Electromed Financials
This page shows Electromed (ELMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Electromed is becoming a scale-efficient device business, with stable gross margins turning revenue growth into disproportionately more cash.
From FY2022 to FY2025, gross margin moved only from75.5% to78.1% , but operating margin more than doubled from7.1% to15.1% , which points to SG&A absorption rather than simple price increases as the main profit engine. Because capex was only$262K in FY2025, that margin improvement translated unusually cleanly into free cash flow of$11.1M .
FY2025 net income of
The balance sheet still looks self-funded: after a
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Electromed's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Electromed has an operating margin of 15.1%, meaning the company retains $15 of operating profit per $100 of revenue. This strong profitability earns a score of 73/100, reflecting efficient cost management and pricing power. This is up from 12.0% the prior year.
Electromed's revenue surged 17.0% year-over-year to $64.0M, reflecting rapid business expansion. This strong growth earns a score of 76/100.
Electromed carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 72/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.31, Electromed holds $4.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
Electromed converts 17.4% of revenue into free cash flow ($11.1M). This strong cash generation earns a score of 76/100.
Electromed earns a strong 17.4% return on equity (ROE), meaning it generates $17 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 79/100. This is up from 11.6% the prior year.
Electromed scores 24.59, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($379.4M) relative to total liabilities ($10.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Electromed passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Electromed generates $1.51 in operating cash flow ($11.4M OCF vs $7.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Electromed generated $64.0M in revenue in fiscal year 2025. This represents an increase of 17.0% from the prior year.
Electromed's EBITDA was $10.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.9% from the prior year.
Electromed reported $7.5M in net income in fiscal year 2025. This represents an increase of 46.3% from the prior year.
Electromed earned $0.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 46.6% from the prior year.
Cash & Balance Sheet
Electromed generated $11.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 26.8% from the prior year.
Electromed held $15.3M in cash against $0 in long-term debt as of fiscal year 2025.
Electromed had 8M shares outstanding in fiscal year 2025. This represents a decrease of 3.3% from the prior year.
Margins & Returns
Electromed's gross margin was 78.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.8 percentage points from the prior year.
Electromed's operating margin was 15.1% in fiscal year 2025, reflecting core business profitability. This is up 3.1 percentage points from the prior year.
Electromed's net profit margin was 11.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.4 percentage points from the prior year.
Electromed's ROE was 17.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.9 percentage points from the prior year.
Capital Allocation
Electromed invested $996K in research and development in fiscal year 2025. This represents an increase of 51.8% from the prior year.
Electromed spent $10.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3536.4% from the prior year.
Electromed invested $262K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.7% from the prior year.
ELMD Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.6M-1.7% | $18.9M+11.9% | $16.9M-2.9% | $17.4M+10.9% | $15.7M-3.5% | $16.3M+10.8% | $14.7M-1.1% | $14.8M |
| Cost of Revenue | $3.9M-3.6% | $4.1M+10.5% | $3.7M-2.1% | $3.8M+9.1% | $3.5M-4.8% | $3.6M+14.2% | $3.2M-10.0% | $3.5M |
| Gross Profit | $14.6M-1.2% | $14.8M+12.3% | $13.2M-3.1% | $13.6M+11.4% | $12.2M-3.2% | $12.6M+9.9% | $11.5M+1.7% | $11.3M |
| R&D Expenses | $361K-6.0% | $384K+59.3% | $241K-20.2% | $302K+9.0% | $277K+10.4% | $251K+51.2% | $166K-5.7% | $176K |
| SG&A Expenses | $10.5M-2.8% | $10.8M+5.1% | $10.3M0.0% | $10.3M+4.8% | $9.8M-0.2% | $9.8M+4.8% | $9.4M+6.8% | $8.8M |
| Operating Income | $3.8M+4.0% | $3.6M+35.6% | $2.7M-12.2% | $3.0M+42.1% | $2.1M-15.8% | $2.5M+31.2% | $1.9M-17.0% | $2.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $152K-22.1% | $195K+20.4% | $162K |
| Income Tax | $863K-10.8% | $968K+44.9% | $668K-31.2% | $971K+148.3% | $391K-46.1% | $726K+10.2% | $659K-1.5% | $669K |
| Net Income | $3.0M+8.8% | $2.8M+29.3% | $2.1M-3.1% | $2.2M+16.6% | $1.9M-3.9% | $2.0M+33.5% | $1.5M-19.4% | $1.8M |
| EPS (Diluted) | $0.35+9.4% | $0.32+28.0% | $0.25 | N/A | $0.21-4.5% | $0.22+37.5% | $0.16 | N/A |
ELMD Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.5M+8.3% | $54.9M+2.4% | $53.6M-0.3% | $53.8M+2.6% | $52.5M+0.3% | $52.3M+6.9% | $48.9M-6.4% | $52.2M |
| Current Assets | $50.2M+10.2% | $45.6M+2.3% | $44.6M-1.2% | $45.1M+2.0% | $44.2M0.0% | $44.2M+7.8% | $41.0M-7.2% | $44.2M |
| Cash & Equivalents | $17.0M+23.2% | $13.8M-2.3% | $14.1M-7.7% | $15.3M+0.3% | $15.2M-6.1% | $16.2M+17.1% | $13.9M-13.8% | $16.1M |
| Inventory | $3.3M-4.7% | $3.5M-8.3% | $3.8M+14.3% | $3.3M+11.2% | $3.0M-3.7% | $3.1M-10.3% | $3.4M-7.5% | $3.7M |
| Accounts Receivable | $28.3M+7.6% | $26.3M+6.1% | $24.8M+0.4% | $24.7M+5.2% | $23.4M+2.9% | $22.8M+1.8% | $22.4M-4.1% | $23.3M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.3M+8.8% | $9.5M+6.8% | $8.9M-16.3% | $10.6M+24.5% | $8.5M-1.8% | $8.7M+16.7% | $7.4M-3.4% | $7.7M |
| Current Liabilities | $10.2M+9.1% | $9.4M+7.0% | $8.8M-16.3% | $10.5M+23.0% | $8.5M-1.8% | $8.7M+16.8% | $7.4M-3.4% | $7.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $49.2M+8.2% | $45.4M+1.6% | $44.7M+3.6% | $43.2M-1.7% | $43.9M+0.8% | $43.6M+5.1% | $41.5M-6.9% | $44.5M |
| Retained Earnings | $25.1M+12.8% | $22.3M-0.1% | $22.3M+5.3% | $21.2M-6.1% | $22.6M-0.1% | $22.6M+9.7% | $20.6M-13.0% | $23.7M |
ELMD Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.5M+14.9% | $3.0M+1690.5% | $169K-95.6% | $3.9M+86.1% | $2.1M-34.2% | $3.2M+36.5% | $2.3M-48.6% | $4.5M |
| Capital Expenditures | $147K-76.8% | $634K+151.6% | $252K+73.8% | $145K+194.8% | -$153K-165.7% | $233K+529.7% | $37K+68.2% | $22K |
| Free Cash Flow | $3.3M+39.2% | $2.4M+2981.9% | -$83K-102.2% | $3.7M+93.3% | $1.9M-34.2% | $2.9M+28.4% | $2.3M-49.1% | $4.5M |
| Investing Cash Flow | -$154K+76.5% | -$656K-145.7% | -$267K-70.1% | -$157K-207.5% | $146K+161.6% | -$237K-308.6% | -$58K-26.1% | -$46K |
| Financing Cash Flow | -$128K+95.2% | -$2.7M-150.2% | -$1.1M+70.5% | -$3.7M-13.5% | -$3.2M-492.6% | -$543K+87.8% | -$4.5M-5856.0% | -$75K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $152K-94.5% | $2.8M+175.5% | $1.0M-72.7% | $3.7M+104.4% | $1.8M | $0-100.0% | $4.5M+1549.5% | $275K |
ELMD Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.8%+0.4pp | 78.4%+0.3pp | 78.1%-0.2pp | 78.3%+0.4pp | 78.0%+0.3pp | 77.7%-0.7pp | 78.3%+2.1pp | 76.2% |
| Operating Margin | 20.3%+1.1pp | 19.2%+3.4pp | 15.8%-1.7pp | 17.5%+3.8pp | 13.6%-2.0pp | 15.6%+2.4pp | 13.2%-2.5pp | 15.7% |
| Net Margin | 16.2%+1.6pp | 14.6%+2.0pp | 12.7%-0.0pp | 12.7%+0.6pp | 12.1%-0.1pp | 12.1%+2.1pp | 10.1%-2.3pp | 12.3% |
| Return on Equity | 6.1%+0.0pp | 6.1%+1.3pp | 4.8%-0.3pp | 5.1%+0.8pp | 4.3%-0.2pp | 4.5%+1.0pp | 3.5%-0.6pp | 4.1% |
| Return on Assets | 5.1%+0.0pp | 5.0%+1.0pp | 4.0%-0.1pp | 4.1%+0.5pp | 3.6%-0.2pp | 3.8%+0.8pp | 3.0%-0.5pp | 3.5% |
| Current Ratio | 4.91+0.1 | 4.86-0.2 | 5.09+0.8 | 4.31-0.9 | 5.19+0.1 | 5.10-0.4 | 5.53-0.2 | 5.75 |
| Debt-to-Equity | 0.210.0 | 0.21+0.0 | 0.20-0.0 | 0.25+0.1 | 0.190.0 | 0.20+0.0 | 0.180.0 | 0.17 |
| FCF Margin | 17.9%+5.3pp | 12.7%+13.1pp | -0.5%-21.8pp | 21.3%+9.1pp | 12.3%-5.7pp | 17.9%+2.5pp | 15.5%-14.6pp | 30.1% |
Similar Companies
Frequently Asked Questions
What is Electromed's annual revenue?
Electromed (ELMD) reported $64.0M in total revenue for fiscal year 2025. This represents a 17.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Electromed's revenue growing?
Electromed (ELMD) revenue grew by 17% year-over-year, from $54.7M to $64.0M in fiscal year 2025.
Is Electromed profitable?
Yes, Electromed (ELMD) reported a net income of $7.5M in fiscal year 2025, with a net profit margin of 11.8%.
What is Electromed's EBITDA?
Electromed (ELMD) had EBITDA of $10.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Electromed's gross margin?
Electromed (ELMD) had a gross margin of 78.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Electromed's operating margin?
Electromed (ELMD) had an operating margin of 15.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Electromed's net profit margin?
Electromed (ELMD) had a net profit margin of 11.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Electromed's return on equity (ROE)?
Electromed (ELMD) has a return on equity of 17.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Electromed's free cash flow?
Electromed (ELMD) generated $11.1M in free cash flow during fiscal year 2025. This represents a 26.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Electromed's operating cash flow?
Electromed (ELMD) generated $11.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Electromed's total assets?
Electromed (ELMD) had $53.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Electromed's capital expenditures?
Electromed (ELMD) invested $262K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Electromed spend on research and development?
Electromed (ELMD) invested $996K in research and development during fiscal year 2025.
What is Electromed's current ratio?
Electromed (ELMD) had a current ratio of 4.31 as of fiscal year 2025, which is generally considered healthy.
What is Electromed's debt-to-equity ratio?
Electromed (ELMD) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Electromed's return on assets (ROA)?
Electromed (ELMD) had a return on assets of 14.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Electromed's Altman Z-Score?
Electromed (ELMD) has an Altman Z-Score of 24.59, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Electromed's Piotroski F-Score?
Electromed (ELMD) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Electromed's earnings high quality?
Electromed (ELMD) has an earnings quality ratio of 1.51x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Electromed?
Electromed (ELMD) scores 77 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.